



**HAL**  
open science

## Extended spectrum beta-lactamase producing bacteria and *Clostridium difficile* in pouchitis patients

Simon D McLaughlin, Sue K Clark, Catherine H Roberts, Zarah L  
Perry-Woodford, Paris Tekkis, Paul Ciclitira, R John Nicholls

► **To cite this version:**

Simon D McLaughlin, Sue K Clark, Catherine H Roberts, Zarah L Perry-Woodford, Paris Tekkis, et al.. Extended spectrum beta-lactamase producing bacteria and *Clostridium difficile* in pouchitis patients. *Alimentary Pharmacology and Therapeutics*, 2010, 10.1111/j.1365-2036.2010.04401.x . hal-00553741

**HAL Id: hal-00553741**

**<https://hal.science/hal-00553741>**

Submitted on 9 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Extended spectrum beta-lactamase producing bacteria and  
Clostridium difficile in pouchitis patients**

Journal:	<i>Alimentary Pharmacology &amp; Therapeutics</i>
Manuscript ID:	APT-0926-2009.R2
Wiley - Manuscript type:	Original Scientific Paper
Date Submitted by the Author:	14-Jun-2010
Complete List of Authors:	McLaughlin, simon; St. Mark's Hospital, Gastroenterology Clark, Sue; St. Mark's Hospital, Surgery Roberts, Catherine; Guy's and St. Thomas' Hospital, Infection Perry-Woodford, Zarah; St. Mark's Hospital, Surgery Tekkis, Paris; Imperial College London, Department of Biosurgery and Surgical Technology Ciclitira, Paul; Guy's and St. Thomas' Hospital, Gastroenterology, Nutritional Sciences Research Nicholls, R; Imperial College London, Department of Biosurgery and Surgical Technology
Keywords:	Pouchitis < Disease-based, Ulcerative colitis < Disease-based, Inflammatory bowel disease < Disease-based, Small intestine < Organ-based

## EDITOR'S COMMENTS TO AUTHOR:

Both reviewers and myself agree that this is an interesting topic and original data. We also still think that the message would have been strengthened by the addition of adequate controls with the prevalence of ESBL+ among non pouch IBD.

Response:

We agree with the editor and reviewer's comments and hope in time to perform a follow-up study which reviews the prevalence of ESBL in pouch patients with and without a previous history of pouchitis.

## REVIEWERS' COMMENTS TO AUTHOR:

Reviewer: 1

Comments for Transmission to the Authors

None

Reviewer: 2

Comments for Transmission to the Authors

Results:

1." Twenty patients had recurrent pouchitis and twenty eight (59%) patients had relapsing pouchitis. All patients with relapsing pouchitis were receiving treatment with maintenance antibiotic therapy... " relapsing pouchitis? it means refractory?

-Response:

-Thank you. We have corrected this typo.

2." ESBL producing organisms were identified in faecal samples from 16 (33%) patients, two of these patients were on two weekly alternating antibiotic treatment. 10 (55.6%) of 18 patients who were ESBL positive had symptoms of active pouchitis." It is not clear if the ESBL positive patients were 16 or 18. If 16:  $10/16=62.5\%$

-Response:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

-This is a typo, the text should read; "10 (62.5%) of 16 patients who were ESBL positive had symptoms of active pouchitis." We have corrected this typo in the manuscript.

3. " In an earlier open-label study reporting 10 patients with pouchitis complicated by extensive pre-pouch ileitis treated with infliximab. Nine achieved clinical remission (29). " , nine achieved clinical remission (29).

-Response:

-Unfortunately this reviewer's comment is not clear to us.

## **R2; Extended spectrum beta-lactamase producing bacteria and Clostridium difficile in pouchitis patients**

SD McLaughlin<sup>1,2,3</sup>, SK Clark<sup>2,4</sup>, CH Roberts<sup>5</sup>, ZL Perry-Woodford<sup>4</sup>, PP Tekkis<sup>2</sup>, PJ Ciclitira<sup>3</sup>, RJ Nicholls<sup>2</sup>

1. Department of Gastroenterology, St. Mark's Hospital, London,
2. Department of Biosurgery and Surgical Technology, Imperial College London,
3. Department of Gastroenterology, Nutritional Sciences Division, King's College London.
4. Department of Surgery, St. Mark's Hospital, London,
5. Department of Infection, Guy's and St Thomas' Hospital, London

### **Corresponding author:**

Dr Simon McLaughlin

Department of Gastroenterology,

St. Mark's Hospital,

London

HA1 3UJ

Email: [simon.mclaughlin@nhs.net](mailto:simon.mclaughlin@nhs.net)

Phone: +44(0)208 2354018

Fax: +44(0)208 2354001

### **Short running title**

ESBL bacteria in pouchitis

### **Keywords:**

Restorative proctocolectomy, ileal pouch-anal anastomosis, Pouchitis, ulcerative colitis, inflammatory bowel disease, familial adenomatous polyposis, ESBL.

**Abstract**

**Background:** Treatment with fluoroquinolones is associated with the development of *Clostridium difficile* and extended spectrum beta lactamase producing bacteria (ESBL). *Clostridium difficile* and ESBL are resistant to many antibiotics and each may cause pouchitis after restorative proctocolectomy (RPC) refractory to empirical antibiotic therapy.

**Aim:** To assess the prevalence and establish risk factors for the development of ESBL and CDT in RPC patients with recurrent or refractory pouchitis under follow-up at our institution over a one year period.

**Method:** An enzyme linked immunosorbent assay was used to detect *Clostridium difficile* toxins (CDT) and a culture technique was used to identify ESBL in faecal samples. All patients had previously received fluoroquinolone treatment.

**Results:** 48 patients (35 (74%) males; median age 42 years) underwent testing at a median interval from RPC of 8 (range 1-25) years. No patient had a positive CDT result but ESBL bacteria were identified in 16 (33%) samples. ESBL positivity was significantly related to pre-pouch ileitis ( $p= 0.035$ ) and maintenance antibiotic therapy ( $p= 0.039$ ).

**Conclusions:** ESBL but not CDT is a common finding in faecal samples from patients with recurrent or refractory pouchitis. Treatment with maintenance antibiotics and pre-pouch ileitis are risk factors for developing ESBL producing bacteria.

**Background:**

Restorative proctocolectomy with ileal pouch-anal anastomosis (RPC) is the surgical procedure of choice for patients with ulcerative colitis (UC) and selected patients with familial adenomatous polyposis (FAP) who require surgery (1).

Pouchitis is the most common cause of morbidity following RPC. The incidence increases with length of follow-up (1) rising to about 50% at five years with a prevalence of clinically significant recurrent or chronic refractory pouchitis in 5-10% of patients.

In addition about 13% of patients with pouchitis will have pre-pouch ileitis, this is a histological entity distinct from Crohn's disease and can be defined as inflammation proximal to the pouch in a patient with pouchitis and characteristic histological features (2). The histological features of the pre-pouch ileum in pre-pouch ileitis are the same as those seen in pouchitis and include colonic phenotypic change (3).

Empirical antibiotic treatment with ciprofloxacin (a fluoroquinolone) or metronidazole or in combination with other antibiotics is effective in chronic pouchitis and pre-pouch ileitis (4-6). Long-term follow up studies have shown that pouchitis is responsible for 10% of all pouch failures (7). The causes for this are not understood but the development of antibiotic resistance is likely to be important. Where patients are exposed to repeated antibiotic treatment, antibiotic resistance or

1  
2  
3 Clostridium *difficile* infection may develop. Clostridium *difficile* is an important cause of treatment  
4 failure in patients presenting with symptoms of pouchitis (8;9) and should be excluded in those with  
5 pouchitis (1;10).  
6

7  
8 Extended spectrum beta-lactamases (ESBL) are bacterial enzymes which are capable of hydrolysing  
9 penicillins, broad-spectrum cephalosporins and monobactams. ESBL producing bacteria are  
10 inherently resistant to many classes of antibiotic because other determinants of resistance are often  
11 linked on the same plasmid (11). Fluoroquinolone resistance in particular is associated with ESBL  
12 producing bacteria (12;13) and exposure to antibiotics including ciprofloxacin and metronidazole is  
13 associated with an increased risk of developing ESBL producing bacteria (14).  
14  
15

16  
17 Faecal carriage of ESBL producing bacteria is uncommon in the general UK community. One group  
18 report that during the period 2004-05 only 1% of 1253 community faecal samples taken from  
19 patients with diarrhoea contained ESBL-producing bacteria (15). Certain patient groups have been  
20 shown to have increased faecal carriage of ESBL producing bacteria, but to the best of our  
21 knowledge this has not previously been studied in IBD or pouchitis patients. One recent UK study  
22 identified ESBL-producing *E. coli* in 40% of asymptomatic nursing home residents (15). In countries  
23 where antibiotics are available without prescription high levels of ESBL carriage in asymptomatic  
24 individuals have been reported. In one study from Saudi Arabia ESBL-producing organisms were  
25 isolated from 13.1% of asymptomatic outpatients (16), a study from Israel reported a prevalence of  
26 8% in patients being admitted to hospital (17). These studies suggest that asymptomatic carriage of  
27 ESBL producing bacteria is common in patients exposed to frequent antibiotic treatment.  
28  
29

30  
31  
32 Recently we have shown that ESBL producing bacteria may in some cases be associated with  
33 antibiotic refractory pouchitis (18). This may be particularly seen in recurrent or refractory pouchitis  
34 which may require frequent courses of antibiotics or continuous maintenance treatment. In practice,  
35 development of resistance to the usually prescribed antibiotics may limit the treatment options to  
36 nitrofurantoin or colistin. Clostridium *difficile* toxin (CDT) has recently been reported to be present  
37 in 18% of stool samples from RPC patients (19) but the prevalence of ESBL producing bacteria is  
38 unknown. It is likely that ESBL producing bacteria in stool may predispose to an increased risk of  
39 resistant pouchitis and pouch failure in the long-term due to failure of medical therapy.  
40  
41  
42

#### 43 44 45 46 **Aim**

47  
48 To assess the prevalence and establish risk factors for the development of ESBL and CDT in RPC  
49 patients with recurrent or refractory pouchitis under follow-up at our institution over a one year  
50 period.  
51

#### 52 53 54 55 **Method**

56  
57 Ethical permission was granted by the Brent and Harrow Research Ethics Committee to collect  
58 prospective and retrospective data on RPC patients entered into the St Mark's Hospital Pouch  
59 Registry. Consecutive patients with recurrent or refractory pouchitis defined as three or more  
60 episodes of pouchitis per year or persistent pouchitis requiring continuous antibiotic treatment (4)  
attending the outpatient clinic were identified over a one year period. Demographic details including

1  
2  
3 age and sex were recorded. Clinical details were also obtained including the presence of  
4 symptomatic pouchitis at the time of testing, the interval from RPC, and a previous history of pre-  
5 pouch ileitis. Information on whether mucosal healing was achieved after four weeks of antibiotic  
6 treatment and whether the patient was taking maintenance antibiotic therapy was also obtained.  
7 Fresh faecal samples were collected by patients themselves during their hospital attendance and  
8 these were transported to the hospital laboratory and analysed without delay. An enzyme linked  
9 immunosorbent assay was used to detect *Clostridium difficile* toxins A and B (Meridian Bioscience,  
10 Cincinnati, Ohio, USA). To identify ESBL producing bacteria in the faecal samples a standard culture  
11 technique as per British Society for Antimicrobial Chemotherapy and HPA guidelines was used  
12 (20). This technique utilises Iso-sensitest agar (Oxoid, Cambridge, UK) which is a non selective media  
13 used for sensitivity testing of gram negative and gram positive organisms. Faecal samples were  
14 inoculated onto Iso-sensitest agar using a sterile swab and a rotary spreader. Antibiotic discs  
15 containing ciprofloxacin, trimethoprim, cephalixin, co-amoxiclav, nitrofurantoin, cefpodoxime,  
16 cefuroxime, and cefixime were added. We incubated plates at 37°C for 18 to 24 hours and recorded  
17 the sensitivity patterns. ESBL status was defined as a zone size to cefpodoxime of  $\geq 25$ mm, as per  
18 British Society for Antimicrobial Chemotherapy guidance (20).  
19  
20  
21  
22  
23

### 24 Statistical analysis

25  
26 SPSS version 15 (SPSS inc. Chicago, Illinois, USA) was used for all statistical analysis. For the  
27 description of data, the median and range were calculated. The Mann-Whitney U test (two tailed)  
28 was used to compare continuous data and a chi-squared test used to compare categorical variables  
29 between the ESBL negative and ESBL positive groups. A two-tailed P-value less than 0.05 was  
30 considered statistically significant. A multivariate analysis using a backwards stepwise regression  
31 technique with a cut-off value of p less than 0.05 was also performed.  
32  
33  
34  
35  
36  
37  
38

### 39 Results

40  
41 48 patients of median age 42 years (range 20-69) and male gender in 35 (71%) were studied. Two  
42 patients had familial adenomatous polyposis (FAP), three indeterminate colitis (IC) and the  
43 remainder had UC. No patient had received regular treatment with a non-steroidal anti-  
44 inflammatory drug (NSAID) in the preceding 6 months. The median interval from RPC to the present  
45 assessment was 8 years (range 1-25). Twenty patients had recurrent pouchitis and twenty eight  
46 (59%) patients had refractory pouchitis. All patients with refractory pouchitis were receiving  
47 treatment with maintenance antibiotic therapy and 10 (20%) of these patients had  
48 symptomatic pouchitis at the time of faecal testing. Of the patients treated with antibiotic  
49 maintenance therapy, the antibiotics used were ciprofloxacin (18) co-amoxiclav (7), colistin (2),  
50 nitrofurantoin (2), cefixime (1), trimethoprim (2). Three patients were on two weekly alternating  
51 antibiotic combination therapy.  
52  
53  
54  
55  
56  
57  
58

59 ESBL producing organisms were identified in faecal samples from 16 (33%) patients, two of these  
60 patients were on two weekly alternating antibiotic treatment. 10 (62.5%) of 16 patients who were  
ESBL positive had symptoms of active pouchitis. Clinical and statistical data for the ESBL positive and

1  
2  
3 ESBL negative groups are shown in Table 1. It can be seen that the presence of ESBL producing  
4 bacteria was not associated with age, sex or the number of years from RPC. Univariate analysis  
5 however identified an association with a history of pre-pouch ileitis complicating pouchitis and of  
6 maintenance antibiotic therapy. Multivariate analysis demonstrated that only pre-pouch ileitis  
7 predicated the development of ESBL-producing bacteria.  
8  
9

10  
11 CDT was not identified in any patient sample.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

Table 1.

## Clinical and statistical data for ESBL positive and ESBL negative groups

	ESBL Negative	ESBL Positive	P value	Odds-ratio (95% confidence interval)
Number of patients (%)	32 (67%)	16 (33%)		
Median age (range) years	42 (21-58)	45 (20-69)	0.991	
Male	22 (67%)	13 (81%)	0.363	2.321 (0.449-12.0)
No. of years from RPC median(range)	8.5 (1-25)	6.5 (2-25)	0.539	0.956 (0.858-1.064)
History of pre-pouch ileitis (%)	8 (50%)	9 (69%)	<b>0.033</b>	3.020 (0.764-11.938)
Maintenance antibiotic therapy (%)	16 (48.5%)	13 (81.3%)	<b>0.037</b>	3.823 (0.801-18.238)
Mucosal healing following antibiotic treatment	14 (44%)	9 (56%)	0.419	

## Discussion

In the light of a recent report indicating that ESBL producing bacteria may in some cases be the cause of antibiotic refractory pouchitis (18), we reviewed the prevalence of ESBL in our RPC patients with recurrent or refractory pouchitis. The study has shown that ESBL producing bacteria occur in 33% of such patients and that maintenance antibiotic therapy and pre-pouch ileitis are associated with a significantly increased risk of ESBL producing bacteria.

None of the patients studied had detectable CDT. This is in contrast with a recent finding by Shen *et al* who studied 115 RPC patients undergoing routine pouchoscopy for surveillance or investigation of pouch dysfunction. These authors reported a prevalence of 18% of which 5% of patients were symptomatic. In their univariate analysis, male gender and a previous history of left sided colitis were associated with an increased risk of CDT after RPC. Surprisingly the previous use of antibiotics

1  
2  
3 was not (19). The reasons for the difference in the prevalence of CDT in the present study and that  
4 of Shen *et al* are unclear but could be related to differences in antibiotic use and the prevalence of  
5 *Clostridium difficile* in the local hospital and community population. There were limitations to our  
6 study. The number of patients was small but this reflects the fact that recurrent or refractory  
7 pouchitis is uncommon in the general RPC population, affecting only about 5% of patients (1).  
8 Patients requiring antibiotic maintenance therapy at our institution are treated with ciprofloxacin  
9 according to our own and others previously published guidelines (1;22). In those where this becomes  
10 ineffective faecal coliform sensitivity testing is performed and an appropriate antibiotic prescribed  
11 according to the sensitivity patterns identified. Therefore all patients treated with maintenance  
12 therapy will have received ciprofloxacin; consequently we were unable to reliably establish whether  
13 different antibiotics are associated with an increased risk of developing ESBL-producing bacteria.  
14  
15  
16  
17

18  
19 On univariate analysis pre-pouch ileitis and long term antibiotic treatment were both associated  
20 with an increased risk of developing ESBL producing bacteria. Of these, pre-pouch ileitis was shown  
21 to be the more important on multivariate analysis. It is known that exposure to antibiotics is  
22 associated with an increased risk of developing ESBL producing bacteria (14) therefore the finding in  
23 the present study is not surprising. Why ESBL producing bacteria are more common in patients with  
24 pouchitis complicated by pre-pouch ileitis than in patients with pouchitis only is less clear. Pre-pouch  
25 ileitis may be due to reflux of pouch contents into the pre-pouch ileum (2). It can be treated with  
26 combination antibiotic therapy (23), suggesting that bacteria are important in its aetiology. The  
27 present study has also shown that patients with pre-pouch ileitis or those treated with maintenance  
28 antibiotic therapy are at increased risk of developing ESBL producing bacteria. It is possible that  
29 pouchitis complicated by pre-pouch ileitis may be associated with a higher bacterial load  
30 predisposing to the development of bacterial resistance (24).  
31  
32  
33  
34

35 The majority of patients with ESBL producing bacteria in this study were asymptomatic. It is possible,  
36 however, that over time symptomatic pouchitis secondary to ESBL-producing bacteria (ESBL  
37 pouchitis) may occur. Treatment of ESBL pouchitis with nitrofurantoin or colistin is effective in most  
38 but not all cases (18) and it is likely that resistance to these antibiotics may develop over time. Thus  
39 it is possible that the carriage of ESBL producing coliforms may be associated with an increased risk  
40 of pouch failure.  
41  
42  
43

44 Strategies to reduce antibiotic use and therefore to reduce the risk of developing EBSL producing  
45 bacteria and *Clostridium difficile* should be considered. We have now adopted the practice that all  
46 patients with symptoms of pouchitis undergo endoscopy to confirm the diagnosis before initiating  
47 antibiotic treatment and we have been careful not to treat patients before the diagnosis is certain.  
48 In patients where a flexible pouchoscopy cannot be arranged promptly, measurement of faecal  
49 calprotectin to confirm a clinical diagnosis of pouchitis is a reasonable alternative (25). Non-  
50 antibiotic treatment would clearly reduce the risk but few effective treatments have been reported.  
51 Oral budesonide was suggested to be useful in patients with refractory pouchitis who did not  
52 respond to single antibiotic therapy (open label study) (26), but unfortunately a randomised double  
53 blind study of budesonide enemas found it no more effective than metronidazole (27). Infliximab  
54 has recently been reported to be efficacious in chronic refractory pouchitis. 10 patients received  
55 Infliximab, and of these seven maintained a clinical response at a median follow up of 8.5 months  
56 (28). In an earlier open-label study reporting 10 patients with pouchitis complicated by extensive  
57 pre-pouch ileitis treated with infliximab. Nine achieved clinical remission (29). Adalimumab has been  
58  
59  
60

1  
2  
3 reported to be effective in RPC patients with Crohn's disease but has not yet been studied in  
4 patients with UC (30). Sulphasalazine has been reported to be an effective treatment for pouchitis.  
5 In an open-label study of 11 patients 63% of patients were in remission after 8 weeks treatment  
6 (31). The probiotic VSL#3 has been shown to be effective in patients with mild to moderate pouchitis  
7 (defined as a PDAI between 7 and 12). In an open-label study Gionchetti *et al* studied 23 patients  
8 who were treated with VSL#3 (900 billion bacteria) twice daily for four weeks. Sixteen (69%) entered  
9 remission. Following this, maintenance treatment was continued with 1800 billion bacteria per day,  
10 and all 16 patients maintained remission for 6 months (32). It is possible that VSL#3 may be an  
11 alternative to antibiotic agents in the treatment of mild to moderate pouchitis.  
12  
13  
14  
15

16 Maintenance therapy with an antibiotic or VSL#3 is recommended in patients with chronic antibiotic  
17 dependent pouchitis (21). Treatment with VSL#3 rather than ciprofloxacin maintenance therapy may  
18 reduce the risk of developing ESBL producing bacteria or *Clostridium difficile*, but evidence of  
19 efficacy is limited to patients with complete (33) or near-complete mucosal (34) healing. This may  
20 partly explain the disappointing results reported in an open-label clinical study (35). Surprisingly  
21 there is no evidence that immunomodulators are useful in pouchitis. Although there are no  
22 controlled studies, two groups have reported the occurrence of pouchitis in patients treated with  
23 azathioprine for primary sclerosing cholangitis (36;37) suggesting that this may not be effective.  
24  
25  
26  
27

28 In conclusion we found no evidence of *Clostridium difficile*, but ESBL producing bacteria occurred in  
29 33% of our patients with recurrent or refractory pouchitis. Further research is required to establish  
30 whether ESBL are common in all RPC patients or as is more likely, occur only in those who have  
31 received antibiotics. Because ESBL pouchitis is difficult to treat, longitudinal studies are warranted to  
32 establish whether the presence of ESBL producing bacteria predisposes to pouch failure. Although  
33 the present study supports the policy that antibiotics for pouchitis should be limited wherever  
34 possible it is, however, unlikely that they can be avoided in most patients with recurrent or  
35 refractory pouchitis.  
36  
37  
38  
39  
40

#### 41 **Financial support**

42  
43 Simon McLaughlin is supported by the St. Mark's Hospital Foundation and the the Broad Medical  
44 Research Program of The Broad Foundation.  
45  
46

#### 47 **Statement of interests**

48  
49 All authors declare that they have no conflicts of interest.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 1. McLaughlin, S. D., Clark, S. K., Tekkis, P. P., Ciclitira, P. J., and Nicholls, R. J. Review Article:  
7 Restorative Proctocolectomy, Indications, Management of Complications and Follow-  
8 Up: a Guide for Gastroenterologists. *Aliment.Pharmacol.Ther.* 9-2-2008.
- 9  
10 2. McLaughlin, S. D., Clark, S. K., Bell, A. J., *et al.* Incidence and Short-Term Implications of  
11 Prepouch Ileitis Following Restorative Proctocolectomy With Ileal Pouch-Anal  
12 Anastomosis for Ulcerative Colitis. *Dis.Colon Rectum* 2009;52(5):879-83.
- 13  
14 3. Bell, A. J., Price, A. B., Forbes, A., Ciclitira, P. J., Groves, C., and Nicholls, R. J. Pre-Pouch Ileitis: a  
15 Disease of the Ileum in Ulcerative Colitis After Restorative Proctocolectomy. *Colorectal*  
16 *Dis.* 2006;8(5):402-10.
- 17  
18 4. Mimura, T., Rizzello, F., Helwig, U., *et al.* Four-Week Open-Label Trial of Metronidazole and  
19 Ciprofloxacin for the Treatment of Recurrent or Refractory Pouchitis.  
20 *Aliment.Pharmacol.Ther.* 2002;16(5):909-17.
- 21  
22 5. Shen, B., Achkar, J. P., Lashner, B. A., *et al.* A Randomized Clinical Trial of Ciprofloxacin and  
23 Metronidazole to Treat Acute Pouchitis. *Inflamm.Bowel.Dis.* 2001;7(4):301-5.
- 24  
25 6. Shen, B., Fazio, V. W., Remzi, F. H., *et al.* Combined Ciprofloxacin and Tinidazole Therapy in  
26 the Treatment of Chronic Refractory Pouchitis. *Dis.Colon Rectum* 7-2-2007.
- 27  
28 7. Tulchinsky, H., Hawley, P. R., and Nicholls, J. Long-Term Failure After Restorative  
29 Proctocolectomy for Ulcerative Colitis. *Ann.Surg.* 2003;238(2):229-34.
- 30  
31 8. Shen, B., Goldblum, J. R., Hull, T. L., *et al.* Clostridium Difficile-Associated Pouchitis. *Dig.Dis.Sci.*  
32 2006;51(12):2361-4.
- 33  
34 9. Mann, S. D., Pitt, J., Springall, R. G., *et al.* Clostridium Difficile Infection--an Unusual Cause of  
35 Refractory Pouchitis: Report of a Case. *Dis.Colon Rectum* 2003;46(2):267-70.
- 36  
37 10. Shen, B. and Lashner, B. Diagnosis and Treatment of Ileal Pouch Diseases in Patients With  
38 Underlying Ulcerative Colitis. *Curr.Treat.Options.Gastroenterol.* 2006;9(1):3-12.
- 39  
40 11. Rupp, M. E. and Fey, P. D. Extended Spectrum Beta-Lactamase (ESBL)-Producing  
41 Enterobacteriaceae: Considerations for Diagnosis, Prevention and Drug Treatment.  
42 *Drugs* 2003;63(4):353-65.
- 43  
44 12. Spanu, T., Luzzaro, F., Perilli, M., *et al.* Occurrence of Extended-Spectrum Beta-Lactamases in  
45 Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to  
46 Beta-Lactams and Other Antimicrobial Drugs. *Antimicrob.Agents Chemother.*  
47 2002;46(1):196-202.
- 48  
49 13. Paterson, D. L., Mulazimoglu, L., Casellas, J. M., *et al.* Epidemiology of Ciprofloxacin Resistance  
50 and Its Relationship to Extended-Spectrum Beta-Lactamase Production in Klebsiella  
51 Pneumoniae Isolates Causing Bacteremia. *Clin.Infect.Dis.* 2000;30(3):473-8.
- 52  
53 14. Bradford, P. A. Extended-Spectrum Beta-Lactamases in the 21st Century: Characterization,  
54 Epidemiology, and Detection of This Important Resistance Threat. *Clin.Microbiol.Rev.*  
55 2001;14(4):933-51, table.
- 56  
57  
58  
59  
60

15. Rooney, P. J., O'Leary, M. C., Loughrey, A. C., *et al.* Nursing Homes As a Reservoir of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Ciprofloxacin-Resistant Escherichia Coli. *J Antimicrob.Chemother.* 2009;64(3):635-41.
16. Kader, A. A., Kumar, A., and Kamath, K. A. Fecal Carriage of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli and Klebsiella Pneumoniae in Patients and Asymptomatic Healthy Individuals. *Infect.Control Hosp.Epidemiol.* 2007;28(9):1114-6.
17. Friedmann, R., Raveh, D., Zartzer, E., *et al.* Prospective Evaluation of Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae Among Patients at Hospital Admission and of Subsequent Colonization With ESBL-Producing Enterobacteriaceae Among Patients During Hospitalization. *Infect.Control Hosp.Epidemiol.* 2009;30(6):534-42.
18. McLaughlin, S. D., Clark, S. K., Shafi, S., *et al.* Fecal Coliform Testing to Identify Effective Antibiotic Therapies for Patients With Antibiotic-Resistant Pouchitis. *Clin.Gastroenterol.Hepatol.* 2009;7(5):545-8.
19. Shen, B. O., Jiang, Z. D., Fazio, V. W., *et al.* Clostridium Difficile Infection in Patients With Ileal Pouch-Anal Anastomosis. *Clin.Gastroenterol.Hepatol.* 2008;6(7):782-8.
20. Laboratory detection and reporting of bacteria with extended spectrum beta-lactamases. Issue no: 2.2 Issue date: 19.05.08 Ref. no. QSOP 51i2. [http://www.hpa-standardmethods.org.uk/pdf\\_sops.asp](http://www.hpa-standardmethods.org.uk/pdf_sops.asp)
21. Adam, B., Liebregts, T., and Holtmann, G. Maintaining Remission of Ulcerative Colitis With the Probiotic Escherichia Coli Nissle 1917 Is As Effective As With Standard Mesalazine. *Z.Gastroenterol.* 2006;44(3):267-9.
22. Carter, M. J., Lobo, A. J., and Travis, S. P. Guidelines for the Management of Inflammatory Bowel Disease in Adults. *Gut* 2004;53 Suppl 5:V1-16.
23. McLaughlin, S. D., Clark, S. K., Bell, A. J., *et al.* An Open Study of Antibiotics for the Treatment of Pre-Pouch Ileitis Following Restorative Proctocolectomy With Ileal Pouch-Anal Anastomosis. *Aliment.Pharmacol.Ther.* 3-10-2008.
24. McLaughlin, S. D., Clark, S. K., Tekkis, P. P., *et al.* An Open Study of Maintenance Antibiotic Therapy for Chronic Antibiotic Dependent Pouchitis; Efficacy, Complications and Outcome. *Colorectal Dis.* 21-12-2009.
25. Johnson MW, Maestranzi S, Duffy AM *et al.* Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. *Eur J Gastroenterol Hepatol* 2008;**20**(3):174-9.
26. Gionchetti, P., Rizzello, F., Poggioli, G., *et al.* Oral Budesonide in the Treatment of Chronic Refractory Pouchitis. *Aliment.Pharmacol.Ther.* 15-5-2007;25(10):1231-6.
27. Sambuelli, A., Boerr, L., Negreira, S., *et al.* Budesonide Enema in Pouchitis--a Double-Blind, Double-Dummy, Controlled Trial. *Aliment.Pharmacol.Ther.* 2002;16(1):27-34.
28. Ferrante, M., D'Haens, G., Dewit, O., *et al.* Efficacy of Infliximab in Refractory Pouchitis and Crohn's Disease-Related Complications of the Pouch: A Belgian Case Series. *Inflamm.Bowel.Dis.* 27-7-2009.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
29. Calabrese, C., Gionchetti, P., Rizzello, F., *et al.* Short-Term Treatment With Infliximab in Chronic Refractory Pouchitis and Ileitis. *Aliment.Pharmacol.Ther.* 2008;27(9):759-64.
  30. Shen, B., Remzi, F. H., Lavery, I. C., *et al.* Administration of Adalimumab in the Treatment of Crohn's Disease of the Ileal Pouch. *Aliment.Pharmacol.Ther.* 1-3-2009;29(5):519-26.
  31. Belluzzi, A., Serrani, M., Roda, G., *et al.* Pilot Study: the Use of Sulfasalazine for the Treatment of Acute Pouchitis. *Aliment.Pharmacol.Ther.* 10-10-2009.
  32. Gionchetti, P., Rizzello, F., Morselli, C., *et al.* High-Dose Probiotics for the Treatment of Active Pouchitis. *Dis.Colon Rectum* 2007;50(12):2075-82.
  33. Gionchetti, P., Rizzello, F., Venturi, A., *et al.* Oral Bacteriotherapy As Maintenance Treatment in Patients With Chronic Pouchitis: a Double-Blind, Placebo-Controlled Trial. *Gastroenterology* 2000;119(2):305-9.
  34. Mimura, T., Rizzello, F., Helwig, U., *et al.* Once Daily High Dose Probiotic Therapy (VSL#3) for Maintaining Remission in Recurrent or Refractory Pouchitis. *Gut* 2004;53(1):108-14.
  35. Shen, B., Brzezinski, A., Fazio, V. W., *et al.* Maintenance Therapy With a Probiotic in Antibiotic-Dependent Pouchitis: Experience in Clinical Practice. *Aliment.Pharmacol.Ther.* 15-10-2005;22(8):721-8.
  36. Rowley, S., Candinas, D., Mayer, A. D., *et al.* Restorative Proctocolectomy and Pouch Anal Anastomosis for Ulcerative Colitis Following Orthotopic Liver Transplantation. *Gut* 1995;37(6):845-7.
  37. Zins, B. J., Sandborn, W. J., Penna, C. R., *et al.* Pouchitis Disease Course After Orthotopic Liver Transplantation in Patients With Primary Sclerosing Cholangitis and an Ileal Pouch-Anal Anastomosis. *Am.J.Gastroenterol.* 1995;90(12):2177-81.